Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
18 Aprile 2023 - 1:00PM
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”)
(NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company,
today announced that Dr. Fahar Merchant, President and CEO of
Medicenna, will participate in a fireside chat and management will
participate in one-on-one meetings at the 2023 Bloom Burton &
Co. Healthcare Investor Conference, which is scheduled to take
place at the Metro Toronto Convention Centre in Toronto from April
25-26, 2023.
Details on the fireside chat are as follows:
2023 Bloom Burton & Co. Healthcare
Investor Conference |
Date: |
Tuesday, April 25, 2023 |
Time: |
3:30 p.m. EDT |
Webcast: |
https://wsw.com/webcast/bloomburton8/mdna/2717440 |
Webcast and replay information for this event
will be available on the Investor Relations section of Medicenna's
website at https://ir.medicenna.com/.
About MedicennaMedicenna is a
clinical stage immunotherapy company focused on the development of
novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines
and first in class Empowered Superkines. Medicenna’s long-acting
IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior
CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor
alpha) affinity thereby preferentially stimulating cancer killing
effector T cells and NK cells. Medicenna’s early-stage BiSKITs™
program, (Bifunctional SuperKine ImmunoTherapies) is designed to
enhance the ability of Superkines to treat immunologically “cold”
tumors. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly
MDNA55), has been studied in 5 clinical trials including a Phase 2b
trial for recurrent GBM, the most common and uniformly fatal form
of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug
status from the FDA and FDA/EMA, respectively.
Further Information
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com
Media Contact
For media inquiries, please contact:
David Melamed, Account Supervisor, Russo Partners, 212-845-4225, david.melamed@russopartnersllc.com
Grafico Azioni Medicenna Therapeutics (NASDAQ:MDNA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Medicenna Therapeutics (NASDAQ:MDNA)
Storico
Da Giu 2023 a Giu 2024